Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy

Radiology and Oncology

Martina Vrankar^1¹ 

[1] Ljubljana, Slovenia^1

关键词: locally advanced NSCLC;    survival;    immunotherapy;    PD-L1 expression;    chemoradiotherapy;   

DOI  :  10.2478/raon-2018-0009

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundStandard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported.

【 授权许可】

Unknown